DNA technology carries several significant disadvantages, from privacy vulnerabilities and diagnostic errors to unintended biological consequences and potential misuse by governments. While tools like genetic testing, gene editing, and forensic DNA analysis have transformed medicine and criminal justice, each comes with real risks that affect ordinary people.
Genetic Privacy Is Hard to Protect
Your DNA is the most personal data you have, and once it’s in a database, you lose meaningful control over it. Consumer DNA testing companies like 23andMe and AncestryDNA collect genetic profiles from millions of people, and that information doesn’t just sit in a vault. Law enforcement agencies have used consumer genetic databases to identify suspects through their relatives, a technique called forensic genetic genealogy. Only a handful of states, including Maryland, Montana, and Utah, have passed laws regulating how police can search these databases.
The federal Genetic Information Nondiscrimination Act (GINA) prevents health insurers and employers from using your genetic data against you, but the law has significant gaps. It does not cover life insurance, long-term care insurance, or disability insurance. That means if a genetic test reveals you carry markers for a serious disease, insurers in those categories can legally use that information to deny coverage or raise your rates. Some states have filled in these gaps with their own laws, but protections vary widely depending on where you live.
Consumer Genetic Tests Are Often Wrong
One of the most striking disadvantages of DNA technology is how unreliable consumer-grade results can be. A study published in Genetics in Medicine found that 40% of disease-risk variants reported in raw data from direct-to-consumer genetic tests were false positives. That means nearly half of the scary-sounding results people receive about their health aren’t real. These errors happen because consumer tests use less rigorous methods than clinical laboratories, but many people act on the results without ever getting confirmation from a medical-grade test.
The consequences aren’t trivial. A false positive for a cancer-risk gene could lead someone to pursue unnecessary surgery or screening. A false negative could provide dangerous reassurance. Either way, consumer DNA health reports create a gap between what people believe about their bodies and what’s actually true.
Forensic DNA Evidence Isn’t Foolproof
DNA evidence is often treated as the gold standard in criminal cases, but the analysis behind it is more error-prone than most jurors realize. The biggest problem arises with DNA mixtures, samples that contain genetic material from multiple people. A 2023 study found that false positive rates climb sharply as the number of contributors increases. For complex mixtures involving six people, false positive rates reached as high as 9% in populations with lower genetic diversity.
Even simple two-person mixtures aren’t immune. For 23% of population groups tested, false positive rates exceeded one in 100,000, even under favorable conditions where one contributor was already known. The accuracy of the analysis also depends on whether the software uses the right reference population. When there’s a mismatch between the suspect’s actual ancestry and the reference group used in the calculation, error rates increase significantly. This means DNA mixture evidence can be particularly unreliable for people from underrepresented or genetically distinct communities, raising serious fairness concerns in criminal trials.
Gene Editing Creates Unpredictable Results
CRISPR, the most widely used gene-editing tool, is often described as molecular scissors that can precisely cut and rewrite DNA. In practice, it’s far less precise than that metaphor suggests. One major problem is mosaicism: when CRISPR is applied to an embryo, the editing doesn’t happen all at once. The tool keeps cutting and modifying DNA across multiple rounds of cell division, which means different cells in the same organism can end up with different genetic changes.
Research on embryos of small aquatic organisms found strong evidence of mosaicism in 9 out of 11 genes tested. The editing activity continued from the single-cell stage through the 32-cell stage and beyond, spanning at least 2.5 hours after the tool was introduced. Each round of cell division created new opportunities for different edits, producing organisms that were genetic patchworks rather than uniformly edited. For any future application in human medicine, this unpredictability poses a fundamental safety problem: you can’t guarantee that every cell in a patient’s body received the intended change, and unintended edits could have consequences that don’t show up for years.
Gene Therapy Carries Cancer Risk
Gene therapy works by inserting new genetic instructions into a patient’s cells, typically using modified viruses as delivery vehicles. The disadvantage is that these viruses don’t always insert the new gene in a safe location. When the gene lands near a stretch of DNA that controls cell growth, it can accidentally switch on a cancer-promoting gene. This process, called insertional mutagenesis, has caused leukemia in patients treated for immune deficiency disorders when the therapeutic gene inserted itself near a growth-control gene called LMO2, triggering its overexpression.
A more recent concern involves a type of cancer immunotherapy that genetically modifies a patient’s own immune cells. In a study of 449 patients who received this treatment, 3.6% developed secondary cancers, with blood cancers appearing at a median of about 10 months and solid tumors at roughly 26 months after treatment. The projected five-year risk for solid tumors was 15.2%. In early 2024, the FDA opened an investigation into several cases where the modified immune cells themselves became cancerous. While the overall incidence remains below 1% for the specific complication of the modified cells turning malignant, the broader pattern of secondary cancers is a real and measurable trade-off of the technology.
GMO Genes Escape Into the Wild
When DNA technology is used to create genetically modified crops, one disadvantage is that the engineered genes don’t stay where they’re planted. Evidence has accumulated that unintended gene escape occurs in canola, corn, cotton, and bentgrass. The escaped genes show up in other crop varieties, wild plants, and hybrids of closely related species.
Canola is a particularly well-documented example. It readily cross-pollinates with a weedy relative, and field experiments have confirmed that herbicide-resistance genes from engineered canola transferred into wild plants, producing weed-like hybrids that were fertile and resistant to herbicides. Bentgrass engineered for golf courses has similarly hybridized with a wild grass species called rabbitfoot grass, confirmed through molecular analysis. Even in plants that reproduce with minimal genetic mixing, engineered herbicide resistance transferred at a rate of about 0.2%. The concern isn’t just ecological. Herbicide-resistant weeds can force farmers to use more toxic chemicals or more intensive farming methods, undermining the original purpose of the technology.
Government Misuse of DNA Databases
DNA technology gives governments powerful tools for surveillance, and not all governments use those tools responsibly. China maintains national DNA databases and has employed biometric surveillance, including genetic data collection, to monitor ethnic minorities in the Xinjiang Uyghur Autonomous Region. Reports to the U.S. Congress document that this surveillance has facilitated the detention and internment of Uyghurs in re-education centers. The combination of DNA databases with AI-enabled facial and voice recognition creates a surveillance infrastructure that can track and control entire populations based on their ethnicity or political activity.
This isn’t a hypothetical risk confined to authoritarian regimes. Any large-scale DNA database, whether built by a government, a healthcare system, or a consumer testing company, concentrates sensitive information in ways that create opportunities for misuse. The technology itself is neutral, but the power it grants to whoever controls the data is not.